Cover Image
市場調查報告書

全球青光眼治療藥市場未來趨勢

Global Glaucoma Therapeutics Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 299635
出版日期 內容資訊 英文 74 Pages
訂單完成後即時交付
價格
Back to Top
全球青光眼治療藥市場未來趨勢 Global Glaucoma Therapeutics Market 2014-2018
出版日期: 2014年04月11日 內容資訊: 英文 74 Pages
簡介

所謂青光眼,是眼球內部的液體壓力增加這樣的眼科疾病,如果不治療將損失視力,也有失明的可能性。青光眼伴隨的視神經損傷正確的原因還沒判明,不過青光眼發生原因,可分為開放性青光眼和隅角閉鎖性青光眼2種。還有為了降低眼內壓,現在主要使用5種治療方法(前列腺素、乙型阻斷劑、特殊接受器促效劑、碳酸酐酵素抑製劑、一定容量的組合)。預計全球青光眼治療藥市場今後(2013∼2018年)的年複合成長率將達到2.53%。

本報告提供全球的青光眼治療藥的市場相關分析,疾病概要(發病率等)治療藥的開發情形、全球整體的市場趨勢(今後5年的預測值)、各類藥物、地區的詳細趨勢、推動、阻礙市場要素與其影響力,再加上主要企業簡介、今後的市場機會等調查資料、考察,並將結果概述為以下內容。

第1章 摘要整理

第2章 簡稱集

第3章 分析範圍

  • 市場概要
  • 主要的產品與服務

第4章 市場分析技術

  • 市場分析的流程
  • 分析方法

第5章 簡介

第6章 市場環境

  • 市場概況
  • 市場規模與其預測
  • 美國市場
  • 歐洲市場
  • 日本市場
  • 波特的五力分析

第7章 開發平台現況

第8章 發病率、得病率

  • 美國
  • 英國
  • 西班牙
  • 德國
  • 日本

第9章 各類型醫藥品的市場分析

第10章 各地區的分析

  • 南北美洲市場
  • 歐非中東(EMEA)地區市場
  • 亞太地區市場

第11章 購買標準

第12章 促進市場成長的要素

第13章 推動因素與其影響力

第14章 市場課題

第15章 推動因素、課題的影響力

第16章 市場趨勢

第17章 市場趨勢與其影響

第18章 供應商環境

  • 競爭方案
    • 近幾年的主要趨勢
    • 企業合併、收購(M&A)
  • 市場佔有率分析
  • 其他著名的供應商

第19章 主要供應商分析

  • Allergen Inc.
    • 產業概要
    • 產業結構
    • 主要資料
    • SWOT分析
  • Merck & Co. Inc.
  • Novartis A.G.
  • Pfizer Inc.

第20章 其他相關分析

圖表一覽

目錄
Product Code: IRTNTR3455

About Glaucoma Therapeutics

Glaucoma is a disease of the eye in which fluid pressure within the eye increases. If left untreated the patient may lose vision and even become blind. The exact etiology of optic nerve damage due to glaucoma is not fully known, but involves mechanical compression and/or decreased blood flow in the optic nerve. Based on whether the cause of the disease is unknown or known, glaucoma is divided into two types, open angle and closed angle glaucoma. Five main classes of medical treatment are currently used to lower intraocular pressure: prostaglandins, beta blockers, alpha adrenergic agonists, carbonic anhydrase inhibitors, and fixed dose combinations.

TechNavio's analysts forecast the Global Glaucoma Therapeutics market will grow at a CAGR of 2.53 percent over the period 2013-2018.

Covered in this Report

The Global Glaucoma Therapeutics market can be divided into five segments: Prostaglandins, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors, and Fixed Dose Combinations. To calculate the market size, the report considers the revenue generated from the sales of various ophthalmic solutions used in the treatment of glaucoma.

TechNavio's report, the Global Glaucoma Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Glaucoma Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • Allergan Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.

Other Prominent Vendors

  • Acadia Pharmaceuticals Inc.
  • AC Immune SA
  • Acorn Biomedical Inc.
  • Advanced Cell Technology Inc.
  • Aerie Pharmaceuticals Inc.
  • Carl Zeiss Meditec Inc.
  • Falcon Pharmaceuticals Ltd.
  • Inotek Pharmaceuticals Corp.
  • Lexicon Pharmaceuticals Inc.
  • Neurotech Pharmaceuticals Inc.
  • NicOx SA
  • Otsuka Holdings Co. Ltd.
  • Phytopharm plc
  • Santen Pharmaceuticals Co. Ltd.
  • Senju Pharmaceutical Co. Ltd.
  • SIFI SpA
  • Valeant Pharmaceuticals International Inc.

Key Market Driver

  • Increasing Prevalence of Eye Disorders.

For a full, detailed list, view our report.

Key Market Challenge

  • Increasing Number of Patent Expirations.

For a full, detailed list, view our report.

Key Market Trend

  • Increase in Awareness of Glaucoma.

For a full, detailed list, view our report.

Key questions answered in this report:

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings
    • Product Profiles

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Glaucoma Therapeutics Market in the US
    • 06.3.1. Market Size and Forecast
  • 06.4. Glaucoma Therapeutics Market in the Europe
    • 06.4.1. Market Size and Forecast
  • 06.5. Glaucoma Therapeutics Market in Japan
    • 06.5.1. Market Size and Forecast
  • 06.6. Five Forces Analysis

07. Pipeline Snapshot

08. Rate of Incidence and Prevalence

  • 08.1.1. US
  • 08.1.2. UK
  • 08.1.3. Spain
  • 08.1.4. Germany
  • 08.1.5. Japan

09. Market Segmentation by Drug Class

10. Geographical Segmentation

  • 10.1. Glaucoma Therapeutics Market in the Americas
    • 10.1.1. Market Size and Forecast
  • 10.2. Glaucoma Therapeutics Market in the EMEA Region
    • 10.2.1. Market Size and Forecast
  • 10.3. Glaucoma Therapeutics Market in the APAC Region
    • 10.3.1. Market Size and Forecast

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

  • 18.1. Competitive Scenario
    • 18.1.1. Key News
    • 18.1.2. Mergers and Acquisitions
  • 18.2. Market Share Analysis 2013
  • 18.3. Other Prominent Vendors

19. Key Vendor Analysis

  • 19.1. Allergen Inc.
    • 19.1.1. Business Overview
    • 19.1.2. Business Segmentation
    • 19.1.3. Key Information
    • 19.1.4. SWOT Analysis
  • 19.2. Merck & Co. Inc.
    • 19.2.1. Business Overview
    • 19.2.2. Business Segmentation
    • 19.2.3. Key Information
    • 19.2.4. SWOT Analysis
  • 19.3. Novartis A.G.
    • 19.3.1. Business Overview
    • 19.3.2. Business Segmentation
    • 19.3.3. Key Information
    • 19.3.4. SWOT Analysis
  • 19.4. Pfizer Inc.
    • 19.4.1. Business Overview
    • 19.4.2. Business Segmentation
    • 19.4.3. Key Information
    • 19.4.4. SWOT Analysis

20. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Glaucoma Therapeutics Market 2013-2018 (US$ billion)
  • Exhibit 3: Glaucoma Therapeutics Market in the US 2013-2018 (US$ billion)
  • Exhibit 4: Glaucoma Therapeutics Market in the Europe 2013-2018 (US$ billion)
  • Exhibit 5: Glaucoma Therapeutics Market in Japan 2013-2018 (US$ billion)
  • Exhibit 6: Global Glaucoma Therapeutics Market Segmentation by Drug Class
  • Exhibit 7: Global Glaucoma Therapeutics Market Segmentation 2013
  • Exhibit 8: Global Glaucoma Therapeutics Market by Geographical Segmentation 2013
  • Exhibit 9: Glaucoma Therapeutics Market in the Americas 2013-2018 (US$ billion)
  • Exhibit 10: Glaucoma Therapeutics Market in the EMEA region 2013-2018 (US$ billion)
  • Exhibit 11: Glaucoma Therapeutics Market in the APAC region 2013-2018 (US$ billion)
  • Exhibit 12: Global Glaucoma Therapeutics Market by Vendor Segmentation 2013
  • Exhibit 13: Business Segmentation of Allergen Inc.
  • Exhibit 14: Business Segmentation of Merck & Co. Inc.
  • Exhibit 15: Business Segmentation of Novartis A.G.
  • Exhibit 16: Business Segmentation of Pfizer Inc.
Back to Top